FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Julie Milstien

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Organizations

Drug Industry

Activities & Behaviors

Living Beings

Anatomy

Cell Line

Co-author Network

Publications

TOP 3
Kaddar Miloud; Marty Makinen; Sarah Schmitt; Julie Milstien
Global support for new vaccine implementation in middle-income countries.
Julie Milstien; Kaddar Miloud
The role of emerging manufacturers in access to innovative vaccines of public health importance.
Julie Milstien; Vicky Cárdenas; James Cheyne; Alan Brooks
WHO policy development processes for a new vaccine: case study of malaria vaccines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Julie Milstien (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kaddar Miloud; Marty Makinen; Sarah Schmitt; Julie Milstien
Global support for new vaccine implementation in middle-income countries.
Vaccine 2013;31 Suppl 2():B81-96.
2010: Julie Milstien; Kaddar Miloud
The role of emerging manufacturers in access to innovative vaccines of public health importance.
Vaccine 2010;28(9):2115-21.
2010: Julie Milstien; Vicky Cárdenas; James Cheyne; Alan Brooks
WHO policy development processes for a new vaccine: case study of malaria vaccines.
Malaria journal 2010;9():182.
2009: Julie Milstien; Alejandro Costa; Suresh Jadhav; Rajeev Dhere
Reaching international GMP standards for vaccine production: challenges for developing countries.
Expert review of vaccines 2009;8(5):559-66.
2008: Julie Milstien; Lidija Kamara; Patrick Lydon; Violaine Mitchell; Steve Landry
The GAVI Financing Task Force: one model of partner collaboration.
Vaccine 2008;26(51):6699-705.
2008: Lidija Kamara; Julie Milstien; Maria Patyna; Patrick Lydon; Ann Levin; Logan Brenzel
Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.
Vaccine 2008;26(51):6717-26.
2008: P Lydon; R Levine; M Makinen; L Brenzel; V Mitchell; Julie Milstien; L Kamara; S Landry
Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
Vaccine 2008;26(51):6706-16.
2008: Amie Batson; Julie Milstien
The GO License: only part of the solution.
Health affairs (Project Hope) 2008;27(1):140-2.
2007: Julie Milstien; Milagritos D Tapia; Samba O Sow; L Keita; Karen L Kotloff
Strengthening immunization in a West African country: Mali.
Education for health (Abingdon, England) 2007;20(3):120.
2007: Julie Milstien; Patrick Gaulé; Kaddar Miloud
Access to vaccine technologies in developing countries: Brazil and India.
Vaccine 2007;25(44):7610-9.
2007: Michael J Brennan; Uli Fruth; Julie Milstien; Rosemary Tiernan; Sergio de Andrade Nishioka; Liliana Chocarro
Development of new tuberculosis vaccines: a global perspective on regulatory issues.
PLoS medicine 2007;4(8):e252.
2006: Julie Milstien; Kaddar Miloud; Marie Paule Kieny
The impact of globalization on vaccine development and availability.
Health affairs (Project Hope) 2006;25(4):1061-9.
2006: Julie Milstien; Kaddar Miloud
Managing the effect of TRIPS on availability of priority vaccines.
Bulletin of the World Health Organization 2006;84(5):360-5.
2005: Julie Milstien
Regulatory pathways for developing market vaccines redux.
Expert review of vaccines 2005;4(3):241-3.
2005: Julie Milstien; Richard A Cash; John Wecker; Daniel Wikler
Development of priority vaccines for disease-endemic countries: risk and benefit.
Health affairs (Project Hope) 2005;24(3):718-28.
2004: Julie Milstien; Lahouari Belgharbi
Regulatory pathways for vaccines for developing countries.
Bulletin of the World Health Organization 2004;82(2):128-33.
2004: Julie Milstien
Regulation of vaccines: strengthening the science base.
Journal of public health policy 2004;25(2):173-89; discussion 190-6.
2003: Julie Milstien
Regulatory pathways for developing market vaccines.
Expert review of vaccines 2003;2(5):599-601.
2003: Julie Milstien
Emergency response vaccines: lessons learned in response to communicable diseases.
Expert opinion on biological therapy 2003;3(7):1121-31.
2003: Philippe Duclos; Alison Delo; Teresa Aguado; Julian Bilous; Maureen Birmingham; Marie Paule Kieny; Julie Milstien; D Wood; Daniel Tarantola
Immunization safety priority project at the World Health Organization.
Seminars in pediatric infectious diseases 2003;14(3):233-9.
2003: Julie Milstien; Syarifah Liza Munira; Susan Loretan McKinney
Issues in selection of DTwP-based combination vaccines.
Vaccine 2003;21(15):1658-64.
2002: Julie Milstien; Scott Lambert
Emergency response vaccines--a challenge for the public sector and the vaccine industry.
Vaccine 2002;21(1-2):146-54.
2002: Julie Milstien; Nora Dellepiane; Scott Lambert; Lahouari Belgharbi; Chris Rolls; Ivana Knezevic; Jacqueline Fournier-Caruana; D Wood; Elwyn Griffiths
Vaccine quality--can a single standard be defined?
Vaccine 2002;20(7-8):1000-3.
2002: J L Di Fabio; Julie Milstien
Implementation of three Rs methods in 3rd World countries.
Developments in biologicals 2002;111():227-9.
2001: Dorothy Xing; R Gaines Das; T O'Neill; Michael J Corbel; Nora Dellepiane; Julie Milstien
Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test.
Vaccine 2001;20(3-4):342-51.
2001: Luis Jodar; Philippe Duclos; Julie Milstien; Elwyn Griffiths; MT Aguado; C John Clements
Ensuring vaccine safety in immunization programmes--a WHO perspective.
Vaccine 2001;19(13-14):1594-605.
2001: HF Hull; R Bruce Aylward; Julie Milstien
Invited commentary: stopping polio immunization.
American journal of epidemiology 2001;153(3):215-6; discussion 217-8.
2001: Julie Milstien
Vaccine vial monitors.
Indian pediatrics 2001;38(1):107-8.
2000: Ushma Mehta; Julie Milstien; Philippe Duclos; Peter I Folb
Developing a national system for dealing with adverse events following immunization.
Bulletin of the World Health Organization 2000;78(2):170-7.
2000: Nora Dellepiane; Elwyn Griffiths; Julie Milstien
New challenges in assuring vaccine quality.
Bulletin of the World Health Organization 2000;78(2):155-62.
1999: Bjørn Blomberg; Mary Ellen Kitler; Julie Milstien; Nora Dellepiane; A Fanning; PY Norval; S Spinaci
Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1999;3(11 Suppl 3):S371-80; discussion S381-7.
1999: Julie Milstien; M Zaffran; D Wood; Elwyn Griffiths
Re: Laboratory tests for live attenuated poliovirus vaccine. Subhash C. Arya; Biologicals, Volume 26, pp. 245-246, 1998.
Biologicals : journal of the International Association of Biological Standardization 1999;27(3):277-8.
1999: J S Lloyd; Julie Milstien
Auto-disable syringes for immunization: issues in technology transfer.
Bulletin of the World Health Organization 1999;77(12):1001-7.
1999: Julie Milstien; Nora Dellepiane
Alternatives and developing countries.
Developments in biological standardization 1999;101():203-8.
1998: Julie Milstien; A Batson
Funding for vaccination.
Lancet 1998;352(9127):579.
1997: M Kane; Julie Milstien
Immunogenicity of low-dose plasma-derived hepatitis B vaccine.
Lancet 1997;350(9084):1102.
1997: Julie Milstien; A Batson; W Meaney
A systematic method for evaluating the potential viability of local vaccine producers.
Vaccine 1997;15(12-13):1358-63.
1997: Julie Milstien; P Evans; A Batson
Cholera vaccines: lessons from Rwanda and elsewhere.
Lancet 1997;349(9056):957-8.
1997: Julie Milstien; S M Lemon; P F Wright
Development of a more thermostable poliovirus vaccine.
The Journal of infectious diseases 1997;175 Suppl 1():S247-53.
1996: Julie Milstien; B G Gellin; M Kane; José Luis Di Fabio; A Homma
Global DTP manufacturing capacity and capability. Status report: January 1995.
Vaccine 1996;14(4):313-20.
1996: V Dietz; Julie Milstien; F van Loon; Stephen L Cochi; J Bennett
Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus.
Bulletin of the World Health Organization 1996;74(6):619-28.
1996: Julie Milstien; S Lemon
Regulatory considerations for new stabilised poliovaccines.
Developments in biological standardization 1996;87():181-9.
1996: Julie Milstien; V Grachev; A Padilla; Elwyn Griffiths
WHO activities towards the three Rs in the development and control of biological products.
Developments in biological standardization 1996;86():31-9.
1994: A Batson; P Evans; Julie Milstien
The crisis in vaccine supply: a framework for action.
Vaccine 1994;12(11):963-5.
1994: HF Hull; N A Ward; B P Hull; Julie Milstien; Ciro A de Quadros
Paralytic poliomyelitis: seasoned strategies, disappearing disease.
Lancet 1994;343(8909):1331-7.
1994: J L Diaz-Ortega; T Forsey; C J Clements; Julie Milstien
The relationship between dose and response of standard measles vaccines.
Biologicals : journal of the International Association of Biological Standardization 1994;22(1):35-44.
1994: S M Lemon; Julie Milstien
The thermostability of vaccines. Technologies for improving the thermostability of the oral poliovirus vaccine.
International journal of technology assessment in health care 1994;10(1):177-84.
1993: N A Ward; Julie Milstien; HF Hull; B P Hull; R J Kim-Farley
The WHO-EPI initiative for the global eradication of poliomyelitis.
Biologicals : journal of the International Association of Biological Standardization 1993;21(4):327-33.
1993: N Ward; Julie Milstien; HF Hull; B Hull
A global overview and hope for the eradication of poliomyelitis by the year 2000.
Tropical and geographical medicine 1993;45(5):198-202.
1990: Julie Milstien; J J Gibson
Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety.
Bulletin of the World Health Organization 1990;68(1):93-108.
1989: F W Rosa; L A Bosco; C F Graham; Julie Milstien; M Dreis; J Creamer
Neonatal anuria with maternal angiotensin-converting enzyme inhibition.
Obstetrics and gynecology 1989;74(3 Pt 1):371-4.
1989: Thomas P Gross; Julie Milstien; J N Kuritsky
Bulging fontanelle after immunization with diphtheria-tetanus-pertussis vaccine and diphtheria-tetanus vaccine.
The Journal of pediatrics 1989;114(3):423-5.
1988: F E Shaw; D J Graham; Harry A Guess; Julie Milstien; J M Johnson; G C Schatz; S C Hadler; J N Kuritsky; E E Hiner; D J Bregman
Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years.
American journal of epidemiology 1988;127(2):337-52.
1987: Julie Milstien; Thomas P Gross; J N Kuritsky
Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing.
Pediatrics 1987;80(2):270-4.
1986: J M Sills; L A Tanner; Julie Milstien
Food and Drug Administration monitoring of adverse drug reactions.
American journal of hospital pharmacy 1986;43(11):2764-70.
1986: Julie Milstien; J N Kuritsky
Erythema multiforme and hepatitis B immunization.
Archives of dermatology 1986;122(5):511-2.
1985: J B Arrowsmith; Julie Milstien; J N Kuritsky; G Murano
Streptokinase and the Guillain-Barré syndrome.
Annals of internal medicine 1985;103(2):302.
1983: R C Dunlap; Julie Milstien; M L Lundquist
Identification and characterization of measles virus 50S RNA.
Intervirology 1983;19(3):169-75.
1979: J Sprague; L J Eron; A S Seifried; Julie Milstien
Cell-free synthesis of measles virus proteins.
Journal of virology 1979;32(2):688-91.
1979: P Noguchi; R Wallace; J Johnson; E M Earley; S O'Brien; S Ferrone; M A Pellegrino; Julie Milstien; C Needy; W Browne; J Petricciani
Characterization of the WIDR: a human colon carcinoma cell line.
In vitro 1979;15(6):401-8.
1978: R Haselkorn; S Schichman; Julie Milstien; J Petricciani
Characteristics of bacteriophage phiV-1 isolated from live virus vaccines.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1978;158(3):383-7.
1978: A S Seifried; P Albrecht; Julie Milstien
Characterization of an RNA-dependent RNA polymerase activity associated with measles virus.
Journal of virology 1978;25(3):781-7.
1977: Julie Milstien; J R Walker; L J Eron
Correlation of virus polypeptide structure with attenuation of poliovirus type 1.
Journal of virology 1977;23(3):811-5.
1977: Julie Milstien; J R Walker; J C Petricciani
Bacteriophages in live virus vaccines: lack of evidence for effects on the genome of rhesus monkeys.
Science (New York, N.Y.) 1977;197(4302):469-70.
1976: J C Petricciani; Julie Milstien
Tests for RNA tumor viruses in cell substrates used in virus vaccine production.
Developments in biological standardization 1976;37():229-34.
1976: J C Petricciani; Julie Milstien; A S Seifried; R E Wallace; J B Johnson; D W McCoy
Safety of viral vaccine cell substrates: a reevaluation.
Journal of the National Cancer Institute 1976;57(4):915-9.
1975: Julie Milstien; J C Petricciani
Screen for type-C ribonucleic acid viruses in vaccines using the ribonucleic acid-dependent deoxyribonucleic acid polymerase assay.
Journal of clinical microbiology 1975;1(4):353-8.
1973: Malcolm Martin; L D Gelb; G C Fareed; Julie Milstien
Reassortment of simian virus 40 DNA during serial undiluted passage.
Journal of virology 1973;12(4):748-57.
1973: L D Gelb; Julie Milstien; Malcolm Martin; S A Aaronson
Characterization of murine leukaemia virus-specific DNA present in normal mouse cells.
Nature: New biology 1973;244(133):76-9.
1972: M W Makinen; Julie Milstien; H Kon
Specificity of interaction of haptoglobin with mammalian hemoglobin.
Biochemistry 1972;11(21):3851-60.
1972: B I Gerwin; Julie Milstien
An oligonucleotide affinity column for RNA-dependent DNA polymerase from RNA tumor viruses.
Proceedings of the National Academy of Sciences of the United States of America 1972;69(9):2599-603.
1971: Julie Milstien; E F Rossomando
Electrooptic studies on the effect of heat treatment on structure in bacteriophage f1.
Virology 1971;46(3):655-62.
1971: E F Rossomando; Julie Milstien
Electro-optic evidence for the control of the structure of bacteriophage f1 by a minor coat protein.
Journal of molecular biology 1971;58(1):187-95.
1970: Julie Milstien; E Charney
Electric dichroism studies: interaction of trifluoroacetic acid with poly (gamma-benzyl L-glutamate).
Biopolymers 1970;9(9):991-1000.
1969: Julie Milstien; T H Fife
Steric effects in the acylation of alpha-chymotrypsin.
Biochemistry 1969;8(2):623-7.
1967: T H Fife; Julie Milstien
Steric effects in the deacylation of acyl-chymotrypsins.
Biochemistry 1967;6(9):2901-7.